Citizens Financial Group Inc RI Has $163,000 Stock Holdings in Allergan plc (NYSE:AGN)

Citizens Financial Group Inc RI grew its stake in Allergan plc (NYSE:AGN) by 54.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 918 shares of the company’s stock after buying an additional 324 shares during the period. Citizens Financial Group Inc RI’s holdings in Allergan were worth $163,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Banque Pictet & Cie SA acquired a new stake in shares of Allergan in the fourth quarter valued at about $4,866,000. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Allergan by 4.9% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 42,775 shares of the company’s stock valued at $8,177,000 after buying an additional 2,000 shares during the period. BTG Pactual Global Asset Management Ltd increased its stake in shares of Allergan by 3.8% in the fourth quarter. BTG Pactual Global Asset Management Ltd now owns 123,204 shares of the company’s stock valued at $23,553,000 after buying an additional 4,559 shares during the period. Cresset Asset Management LLC increased its stake in shares of Allergan by 5.9% in the fourth quarter. Cresset Asset Management LLC now owns 1,640 shares of the company’s stock valued at $313,000 after buying an additional 92 shares during the period. Finally, Savior LLC acquired a new stake in shares of Allergan in the fourth quarter valued at about $41,000. 83.91% of the stock is owned by institutional investors.

Shares of Allergan stock opened at $193.02 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.84 and a current ratio of 1.01. Allergan plc has a 52 week low of $114.27 and a 52 week high of $202.21. The stock has a 50 day moving average price of $185.22 and a two-hundred day moving average price of $187.00. The stock has a market capitalization of $63.50 billion, a PE ratio of -12.07, a price-to-earnings-growth ratio of 1.63 and a beta of 1.20.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 15th. Shareholders of record on Thursday, April 16th will be paid a $0.74 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.96 dividend on an annualized basis and a yield of 1.53%. Allergan’s dividend payout ratio (DPR) is presently 16.78%.

Several research firms recently commented on AGN. Cfra cut Allergan from a “buy” rating to a “hold” rating in a research note on Wednesday, March 25th. SunTrust Banks cut Allergan from a “buy” rating to a “hold” rating and raised their target price for the stock from $191.00 to $193.00 in a research note on Tuesday, April 21st. Finally, ValuEngine raised Allergan from a “sell” rating to a “hold” rating in a research note on Tuesday, March 24th. Fourteen analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Allergan has an average rating of “Hold” and an average target price of $183.73.

Allergan Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.

See Also: What is a Market Correction?

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.